483 RESPONSE
Eli Lilly & CompanyFDA 483_RESPONSE - Eli Lilly & Company - March 16, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
This 483 RESPONSE record concerns Eli Lilly & Company, with an inspection on March 16, 2021, issued by the Division of Pharmaceutical Quality Operations I, covering drugs.
Open in Dashboard
ID · 48bca0f9-fb52-4f51-9e65-4d0fd6283a21
Violation Codes1
21 CFR 210
Full citation text and observation details available on the Dashboard.